Natural History of Photoreceptor Degeneration in USH1B: Clinical Parameters and Validation of Functional Vision Tests in MYO7A
Recruiting
Observational Study
Usher Syndrome
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
Ready to participate?
Review the details below, then apply to join this clinical trial.
At a Glance
Age
3 – 75
Sex
Any
Study type
Observational
Participants needed
60 (estimated)
Sponsor
Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts · Other
Who this trial is looking for
This trial is looking for people with Usher Syndrome type 1 who are at least 3 years old. Participants will help researchers learn more about vision loss and test new ways to measure vision using virtual reality.
Are You a Good Fit for This Trial?
You may be able to join if
I am at least 3 years old.
I have been diagnosed with Usher Syndrome type 1 in both eyes.
I have a social security system affiliation.
I can understand spoken and signed French.
I have a cochlear implant.
I am between 18 and 75 years old.
You may not be able to join if
I cannot participate in all study visits.
I am expected to enter another treatment trial during this study.
I have serious eye problems other than retinitis pigmentosa.
I have participated in a previous gene replacement trial.
I am pregnant, delivering, or breastfeeding.
I am under judicial or administrative custody.
I am under legal protection measures or cannot give consent.
Summarized in plain language from this trial's official eligibility criteria.
The full criteria are further down this page — only the research team can
confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Inherited retinal diseases (IRDs) are a group of degenerative disorders that cause progressive vision loss. Retinitis pigmentosa (RP) is the most common form, with a global prevalence of approximately 1 in 4,500. About 20-30% of these cases are syndromic, most notably Usher syndrome (USH), which combines hearing loss with visual impairment. Usher syndrome type 1 (USH1), the most severe form, prese…
Inherited retinal diseases (IRDs) are a group of degenerative disorders that cause progressive vision loss. Retinitis pigmentosa (RP) is the most common form, with a global prevalence of approximately 1 in 4,500. About 20-30% of these cases are syndromic, most notably Usher syndrome (USH), which combines hearing loss with visual impairment. Usher syndrome type 1 (USH1), the most severe form, presents at birth with profound sensorineural hearing loss, vestibular areflexia, and early-onset retinal degeneration. Biallelic mutations in the MYO7A gene, which define the USH1B subtype, account for 70% of USH1 cases. There is currently no treatment available for this serious condition. The objective of the study is to characterize the natural history of retinal degeneration in USH1B patients and to validate functional vision tests using virtual reality and patient-reported outcome questionnaires.
Trial Locations
Loading…
Loading trial locations…
Facility
City
State
Country
Status
Eligibility Criteria
Inclusion Criteria:
* Be at least 3 years old;
* Have a clinical diagnosis of USH1 in both eyes, meaning subjects with congenital profound deafness, vestibular dysfunction, and rod dystrophy, carrying biallelic class 4 or 5 variants in the MYO7A gene;
* Be affiliated with or beneficiary of a social…
Inclusion Criteria:
* Be at least 3 years old;
* Have a clinical diagnosis of USH1 in both eyes, meaning subjects with congenital profound deafness, vestibular dysfunction, and rod dystrophy, carrying biallelic class 4 or 5 variants in the MYO7A gene;
* Be affiliated with or beneficiary of a social security system (according to article L1121-8-1 of the French Public Health Code);
For participants in the MOST-VR mobility test and VR-ViSA visual search test (Streetlab), additional criteria apply:
* Sufficient knowledge of spoken and signed French to ensure understanding of tasks and instructions;
* Have a cochlear implant allowing comprehension of auditory instructions for the virtual reality mobility test and a MMSE score ≥ 20/25;
* Age between 18 and 75 years.
Exclusion Criteria:
* Unable to participate in all study visits;
* Expected to enter an experimental treatment trial at any time during this study;
* Presence of ocular conditions that may affect eye status other than retinitis pigmentosa (e.g., history of retinal detachment, glaucoma, vein occlusion, diabetic retinopathy, etc.);
* Participation in the previous gene replacement trial (USHSTAT, NCT01505062);
* Pregnant, delivering, or breastfeeding women (according to article L1121-5 of the French Public Health Code);
* Persons deprived of liberty by judicial or administrative decision (article L1121-6 of the French Public Health Code);
* Adults under legal protection measures or unable to provide consent (article L1121-8 of the French Public Health Code).
For participants in the MOST-VR mobility and VR-ViSA visual search tests, the following non-inclusion criteria apply:
* MMSE score without visual items ≤ 20/25;
* Physical or cognitive impairment that could interfere with mobility;
* Medication that may cause motor, visual, or cognitive disorders (e.g., APS, neuroleptics) or interfere with study assessments.
Picking one helps us show the most relevant trials first.
Your results are loading in the background — you can
change this any time from the results page.
Set your location to continue
Find My Trials uses your location to surface clinical trials near you.
Add your city or zip code to your profile and try again.